Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹942.45
8.30 (0.87%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹5.39K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
38.6
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹622+51.5%
52W High₹1,020.7-7.7%
Current Price
₹942.45
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹753.96
Upper Circuit₹1,130.94
Reference Price
₹942.45
Investment Checklist
Rounding Bottom on 1W (BREAKOUT CONFIRMED) — target ₹1002.62
Inverse Head and Shoulders on 1W (BREAKOUT CONFIRMED) — target ₹907.9
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 45.96 (BUY) with 85.2% confidence
RSI at 73.0 — overbought, pullback risk
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
85%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
877.55
EMA50
824.66
EMA200
794.42
Price Action
UPTREND
BULLISH
Higher Highs7
Higher Lows6
Lower Highs1
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹954.00
₹1020.70
Support (Below)
₹936.80
₹921.50
₹881.40
₹848.98
₹831.95
Volume Analysis
TrendINCREASING
Change+111.40%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bullish Cross
3 days ago
BUY
Stop Loss Levels
Fixed Risk
1% Risk₹933.03
3% Risk₹914.18
5% Risk₹895.33
7% Risk (Custom)
₹876.48Technical Levels
1x ATR (Volatility)₹903.70
2x ATR (Swing)₹864.95
3x ATR (Trend)₹826.20
Immediate Support₹936.80
Moving Averages
EMA 9 (Short-term)₹904.35
EMA 20 (Medium-term)₹877.55
EMA 50 (Trend)₹824.66
EMA 200 (Long-term)₹794.42
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹305.5 Cr | ₹351.5 Cr | ₹380.4 Cr | ₹450.3 Cr |
| Net Profit | ₹29.6 Cr | ₹31 Cr | ₹29.7 Cr | ₹42.1 Cr |
| EPS | — | ₹5.42 | ₹5.18 | ₹7.37 |
| Operating Profit | ₹50.9 Cr | ₹56.6 Cr | ₹56.1 Cr | ₹71.1 Cr |
ROE
13.37%
ROCE
13.35%
Debt/Equity
0.35
Current Ratio
1.99
OPM
15.78%
NPM
9.36%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 30 Jan 2026 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for INNOVACAP
View AllNEWS
positive
Business Standard - Markets 36d ago
Innova Captab consolidated net profit rises 28.78% in the March 2026 quarter
Sales rise 42.28% to Rs 447.80 crore
INNOVACAPHealthcare